FRANK KARBE - 15 Sep 2022 Form 4 Insider Report for Better Therapeutics, Inc.

Role
Chief Executive Officer, President, Treasurer and Secretary, Director
Signature
/s/ Mark Heinen, Attorney-in-Fact
Issuer symbol
BTTX on OTC
Transactions as of
15 Sep 2022
Net transactions value
+$104,695
Form type
4
Filing time
15 Sep 2022, 20:53:54 UTC
Previous filing
07 Jul 2022
Next filing
12 Apr 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BTTX Common Stock Purchase $104,695 +50,000 $2.09 50,000 15 Sep 2022 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.06 to $2.10, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

Remarks:

Chief Executive Officer, President, Treasurer and Secretary